CMS May Review Rx Prices In Medicare Bids; “Non-Interference” Has Limits
Executive Summary
The Medicare Part D implementing regs would allow CMS to ask drug plan sponsors to provide detailed descriptions of manufacturer-level prices and rebates in cases where bids appear "unusually" high or low
You may also be interested in...
PBMs Still Skeptical Of Part D; Is “Donut Hole” A Lifesaver?
Potential Medicare prescription drug insurance plan providers should consider the "donut hole" to be a form of reinsurance that limits their exposure to risk, the Centers for Medicare & Medicaid Services suggests
CMS Shutdown Of Drug Pricing Site In 2006 Will Create “Chaos” – Scully
Consumers will "flip out" when the Centers for Medicare & Medicaid Services shuts down the price comparison website for drug discount cards in January 2006, former Centers for Medicare & Medicaid Services administrator Tom Scully predicts
HHS Rx Price Negotiations Could Gain Bipartisan Support, Consultant Says
Congress will move to strike down the Medicare Rx law's "non-interference" provision in the next two years, former Senate Finance Committee health advisor Kathleen Means said at the Biotechnology Industry Organization's annual conference in San Francisco June 9